Examkin

Question

Difficulty: Very hardBipolar and Related Disorders

A 34-year-old woman comes to the outpatient psychiatry clinic reporting that she "cannot get out of bed" and feels completely hopeless. Over the past 6 weeks, she has experienced a persistently depressed mood, slept 14 hours a day, gained 4.5 kg (10 lb), and suffered from profound fatigue. She admits to passive suicidal ideation but denies any active plan. Her past psychiatric history is notable for a major depressive episode at age 22, for which she was prescribed paroxetine. Three weeks after starting paroxetine, she developed a severely elevated mood, rapid and pressured speech, decreased need for sleep (2 hours per night), and grandiose delusions resulting in psychiatric hospitalization. She was stabilized on a medication that she discontinued 5 years ago because she "felt fine." Her medical history includes type 2 diabetes mellitus, hypertension, and osteoarthritis. Current medications are metformin, lisinopril, hydrochlorothiazide, and daily ibuprofen. Her vital signs show a blood pressure of 145/90 mmHg. Her BMI is 38 kg/m². Laboratory studies reveal a hemoglobin A1c of 9.2%. Mental status examination shows marked psychomotor retardation, a flattened affect, and a depressed mood. Which of the following is the most appropriate next step in pharmacotherapy for this patient's current psychiatric symptoms?

  1. A
    Initiate sertraline
  2. B
    Initiate lithium carbonate
  3. Initiate lurasidoneAnswer
  4. D
    Initiate olanzapine-fluoxetine
  5. E
    Initiate venlafaxine

Answer

Initiate lurasidone
The patient's history of a manic episode (hospitalization, grandiose delusions, decreased need for sleep) following paroxetine use indicates a definitive diagnosis of Bipolar I disorder. She is currently experiencing a severe, acute bipolar depressive episode. The primary goal of pharmacotherapy is to treat the depression without precipitating a manic switch, while minimizing adverse effects given her severe medical comorbidities. Lurasidone is an atypical antipsychotic FDA-approved for acute bipolar depression. Crucially, it has a highly favorable metabolic profile (weight and lipid neutral), making it the safest and most effective choice for a patient with severe obesity and uncontrolled type 2 diabetes (HbA1c 9.2%). Furthermore, it does not have severe pharmacokinetic interactions with her antihypertensives or NSAIDs.

Step-by-Step Solution

1
Diagnose the underlying psychiatric disorder based on past history.
Bipolar I disorder, currently in a severe major depressive episode.
The history of hospitalization for mania (grandiose delusions, decreased need for sleep) triggered by paroxetine confirms Bipolar I disorder, not recurrent major depressive disorder.
2
Identify appropriate medication classes for acute bipolar depression.
Options include lurasidone, quetiapine, cariprazine, olanzapine-fluoxetine, or lithium.
Standard antidepressant monotherapies (SSRIs, SNRIs) must be explicitly avoided due to the high risk of precipitating a manic switch.
3
Evaluate the safety of lithium given the patient's current medication list.
Lithium is unsafe and highly contraindicated in this specific clinical context.
The concurrent use of ACE inhibitors (lisinopril), thiazide diuretics (hydrochlorothiazide), and NSAIDs (ibuprofen) drastically reduces renal lithium clearance, placing the patient at immediate risk for severe lithium toxicity.
4
Evaluate the remaining atypical antipsychotics against the patient's medical comorbidities.
Lurasidone is the most appropriate and optimal choice.
Olanzapine-fluoxetine and quetiapine have high metabolic liabilities and would exacerbate her uncontrolled type 2 diabetes (HbA1c 9.2%) and severe obesity. Lurasidone is metabolically neutral.

Key Concept

Pharmacologic management of acute bipolar depression in patients with complex medical comorbidities and polypharmacy.
Rate this question

Topics

Bipolar and Related Disorders

More questions from this topic